

Title (en)

INDUCTION OF A STRONG IMMUNE RESPONSE TO A SELF-TUMOR ASSOCIATED ANTIGEN

Title (de)

INDUKTION EINER STARKEN IMMUNANTWORT GEGEN EIN TUMOR-ASSOZIIERTES SELBST-ANTIGEN

Title (fr)

INDUCTION D'UNE FORTE REPONSE IMMUNITAIRE A UN AUTO-ANTIGENE ASSOCIE AUX TUMEURS

Publication

EP 1221961 A4 20040331 (EN)

Application

EP 00970926 A 20001013

Priority

- US 0028517 W 20001013
- US 15915399 P 19991013

Abstract (en)

[origin: WO0126672A1] The present invention relates to a method for enhancing the efficacy of an immune response against an antigen which is a self-antigen. The method of the invention comprises (i) immunization of a host with a mimic of the self-antigen to break tolerance to a self antigen, and (ii) increasing the response to the self-antigen by a booster with the original antigen. An immune response may be generated against any self antigen including, for example, tumor associated antigens, cell surface receptors, receptor ligands, cytokines, hormones, or a self antigen whose expression is associated with a disease or disorder. The method of the invention may be used to target destruction of targeted tumor cells bearing tumor associated antigens in cancer subjects through induction of an immune response.

IPC 1-7

A61K 38/00; **C07K 16/42**; **A61K 39/00**; **A61K 31/70**; **A61K 39/40**; **A61K 39/42**; **A61K 39/44**; **A01N 43/04**; **A61K 39/395**; **C07K 7/08**

IPC 8 full level

A61K 48/00 (2006.01); **A61K 38/00** (2006.01); **A61K 39/00** (2006.01); **A61P 35/00** (2006.01); **C07K 16/42** (2006.01)

CPC (source: EP US)

A61K 39/00119 (2018.08 - EP US); **A61P 35/00** (2018.01 - EP); **C07K 16/4266** (2013.01 - EP); **A61K 2039/505** (2013.01 - EP); **A61K 2039/53** (2013.01 - EP)

Citation (search report)

- [XY] WO 9723237 A1 19970703 - IMMUNOMEDICS INC [US], et al
- [PX] WO 0038515 A1 20000706 - NEW YORK MEDICAL COLLEGE [US], et al
- [A] US 5780029 A 19980714 - FERRONE SOLDANO [US]
- [A] EP 0759442 A1 19970226 - ONCOGEN [US]
- [XY] DURRANT L G ET AL: "Development of second generation monoclonal antibodies recognising Lewis-y/lb antigen by anti-idiotypic immunisation", HYBRIDOMA, vol. 12, no. 6, 1993, pages 647 - 660, XP008005496, ISSN: 0272-457X
- [Y] DYALL R ET AL: "HETEROCLITIC IMMUNIZATION INDUCES TUMOR IMMUNITY", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 188, no. 9, 2 November 1998 (1998-11-02), pages 1553 - 1561, XP002947142, ISSN: 0022-1007
- [Y] FERRONE SOLDANO: "Active specific immunotherapy of human melanoma with mouse anti-idiotypic (anti-id) monoclonal antibodies (MAB)", MEDICAL INTELLIGENCE UNIT; IMMUNOTHERAPY OF MALIGNANT MELANOMA, 1996, Chapman and Hall, Inc., 29 West 35th Street, New York, New York, USA; Chapman and Hall Ltd., 2-6 Boundary Row, London SE1 8HN, England, pages 73 - 95, XP009024959, ISBN: 0-412-10491-1
- [A] PARKHURST M R ET AL: "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 SEP 1996, vol. 157, no. 6, 15 September 1996 (1996-09-15), pages 2539 - 2548, XP002096010, ISSN: 0022-1767
- [A] ROSENBERG S A ET AL: "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 3, 1 March 1998 (1998-03-01), pages 321 - 327, XP002091661, ISSN: 1078-8956
- [PA] WANG X ET AL: "IMMUNOTHERAPY OF MELANOMA: PEPTIDE MIMICS OF A HUMAN HIGH MOLECULARWEIGHT-MELANOMA ASSOCIATED ANTIGEN", MEDICINA, BUENOS AIRES, AR, vol. 60, no. SUPPL 2, August 2000 (2000-08-01), pages 48 - 50, XP001053496, ISSN: 0025-7680
- See also references of WO 0126672A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0126672 A1 20010419; **WO 0126672 A9 20020801**; AU 8024100 A 20010423; CA 2385186 A1 20010419; EP 1221961 A1 20020717; EP 1221961 A4 20040331; JP 2003514774 A 20030422

DOCDB simple family (application)

US 0028517 W 20001013; AU 8024100 A 20001013; CA 2385186 A 20001013; EP 00970926 A 20001013; JP 2001529734 A 20001013